A new study from UC San Diego suggests that semaglutide, a GLP-1 drug, may slow biological aging. - The drug slowed biological aging by 9% as measured by the DunedinPACE epigenetic clock.
- It reduced risks of all-cause mortality and age-related diseases. - Effects were linked to reduced inflammation and visceral fat.
- The study involved adults with HIV, but findings may apply broadly. Further research is needed to confirm these results and explore optimal use.